



SUVEN Life Sciences Ltd

News Release

Suven Revenue up by 9.98%; PAT up by 32.77% for 9 months ended December 2016

HYDERABAD, INDIA (1 Feb' 2017) – SUVEN LIFE Sciences Limited, a biopharmaceutical company specialized in CRAMS for global life science companies and drug discovery and developmental activities in Central Nervous System disorders, today announced its Un-audited financial results for the quarter ended 31st December 2016. The Un-audited financial results were reviewed by the audit committee and approved by the Board of Directors in their meeting held on 1st Feb' 2017 at Hyderabad.

Financial Highlights for the 3rd Quarter ended December' 2016 (QoQ):

Growth in income INR 1204 Mn vs 1223 Mn - down by 1.51%

Growth in PAT INR 242 Mn vs 264 Mn - down by 8.65%

Growth in EBIDTA INR 418 Mn vs 436 Mn - down by 4.29%

Financial Highlights for the 9 months' period ended December' 2016:

Growth in income INR 3805 Mn vs 3460 Mn - up by 9.98%

Growth in PAT INR 831 Mn vs. 626 Mn - up by 32.77%

Growth in EBIDTA INR 1333 Mn vs 960 Mn - up by 38.90%

Suven's expenses on innovative R&D in Drug Discovery stood at INR 457 Mn (12% on revenue) for the 9 months' period ended Dec' 2016.

The Board has declared an Interim Dividend of Re. 1 per share (100% of face value of Rs. 1.00 each).

For more information on Suven please visit our Web site at <http://www.suven.com>

Risk Statement:

Except for historical information, all of the statements, expectations and assumptions, including expectations and assumptions, contained in this news release may be forward-looking statements that involve a number of risks and uncertainties. Although Suven attempts to be accurate in making these forward-looking statements, it is possible that future circumstances might differ from the assumptions on which such statements are based. Other important factors which could cause results to differ materially including outsourcing trends, economic conditions, dependence on collaborative partnership programs, retention of key personnel, technological advances and continued success in growth of sales that may make our products/services offerings less competitive;